Illumina Inc Revenue Growth Rates (ILMN), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Illumina Inc   (NASDAQ: ILMN)
 

ILMN's Revenue Growth by Quarter and Year

Illumina Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ILMN Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 1,159.00
1st Quarter March 1,091.00
FY 2,250.00

ILMNs Annual Revenue
Illumina Inc 's Revenue in the fiscal year 2025 $ 4,343.00 millions
Illumina Inc 's Revenue in the fiscal year 2024 $ 4,372.00 millions
Illumina Inc 's Revenue in the fiscal year 2023 $ 4,504.00 millions
Illumina Inc 's Revenue in the fiscal year 2022 $ 4,584.00 millions
Illumina Inc 's Revenue in the fiscal year 2021 $ 4,526.00 millions




ILMN Revenue second quarter 2026 Y/Y Growth Comment
Illumina Inc reported Revenue growth of 9.44% year on year in the second quarter 2026, to $ 1,159.00 millions, this is lower than Illumina Inc 's recent average Revenue increase of 12.4%.

Looking into second quarter 2026 results within Laboratory Analytical Instruments industry 14 other companies have achieved higher Revenue growth. While Illumina Inc ' s Revenue increase of 9.44% ranks overall at the positon no. 2529 in the second quarter 2026.


ILMN Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 4.98 % -1.6 % 3.51 %
3rd Quarter September - 0.37 % -3.49 % 0.36 %
2nd Quarter June 9.44 % -4.77 % -5.44 % 1.2 %
1st Quarter March 4.8 % -3.25 % -1.01 % -11.12 %
FY   - -0.66 % -2.93 % -

Financial Statements
Illumina Inc 's second quarter 2026 Revenue $ 1,159.00 millions ILMN's Income Statement
Illumina Inc 's second quarter 2025 Revenue $ 1,059.00 millions Quarterly ILMN's Income Statement


ILMN Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 6.92 % 2.22 % 0.27 %
3rd Quarter September - 2.36 % -2.88 % -4.85 %
2nd Quarter June 6.23 % 1.73 % 3.35 % 8.19 %
1st Quarter March -5.87 % -5.71 % -4.1 % 0.28 %
FY (Year on Year)   - -0.66 % -2.93 % -


Back to ILMN Growth rate Comparisons >> Back to ILMN Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #15
Healthcare Sector #365
Overall #2529

Revenue Y/Y Growth Statistics
High Average Low
83.62 % 12.4 % -8.58 %
(Dec. 30, 2015)   (Jan 03 2021)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #15
Healthcare Sector #365
Overall #2529
Revenue Y/Y Growth Statistics
High Average Low
83.62 % 12.4 % -8.58 %
(Dec. 30, 2015)   (Jan 03 2021)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Illumina Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
25.43 % 3.02 % -26.31 %
(Sep 27 2020)  


ILMN's II. Quarter Q/Q Revenue Comment
Illumina Inc achieved in the II. Quarter 2026 above company average sequential Revenue increase of 6.23%, to $ 1,159.00 millions, from $1,091.00 millions in the first quarter.
ILMN is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Laboratory Analytical Instruments industry 5 other companies have achieved higher Revenue quarter on quarter growth. While Illumina Inc 's Revenue growth quarter on quarter, overall rank is 1005.


Revenue Q/Q Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #6
Healthcare Sector #149
Overall #1005
Revenue Q/Q Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #6
Healthcare Sector #149
Overall #1005
Revenue Q/Q Growth Statistics
High Average Low
25.43 % 3.02 % -26.31 %
(Sep 27 2020)  


ILMN's II. Quarter Q/Q Revenue Comment
Illumina Inc achieved in the II. Quarter 2026 above company average sequential Revenue increase of 6.23%, to $ 1,159.00 millions, from $1,091.00 millions in the first quarter.
ILMN is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Laboratory Analytical Instruments industry 5 other companies have achieved higher Revenue quarter on quarter growth. While Illumina Inc 's Revenue growth quarter on quarter, overall rank is 1005.


Illumina Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 28 2026)		 12 Months Ending
(Mar 29 2026)		 12 Months Ending
(Dec 28 2025)		 12 Months Ending
(Sep 28 2025)		 12 Months Ending
(Jun 29 2025)
Cumulative Revenue 12 Months Ending $ 4,493.00 $ 4,393.00 $ 4,343.00 $ 4,288.00 $ 4,284.00
Y / Y Revenue Growth (TTM) 4.88 % 1.29 % -0.66 % -2.32 % -3.27 %
Year on Year Revenue Growth Overall Ranking # 2884 # 722 # 1809 # 2157 # 2141
Seqeuential Revenue Change (TTM) 2.28 % 1.15 % 1.28 % 0.09 % -1.22 %
Seq. Revenue Growth (TTM) Overall Ranking # 2724 # 670 # 1660 # 2171 # 2190


Cumulative Revenue growth Comment
Although Illumina Inc 's Annual Revenue growth year on year were below company's average 12.13% , Revenue announced in the Jun 28 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 4.88% year on year, from 1.29% in Mar 29 2026.

In the Healthcare sector 406 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 722 to 2884.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry # 17
Healthcare Sector # 407
Overall # 2884

Revenue TTM Y/Y Growth Statistics
High Average Low
47.56 %
 12.13 %
-8.58 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 17
Sector # 388
S&P 500 # 2724
Cumulative Revenue growth Comment
Although Illumina Inc 's Annual Revenue growth year on year were below company's average 12.13% , Revenue announced in the Jun 28 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 4.88% year on year, from 1.29% in Mar 29 2026.

In the Healthcare sector 406 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 722 to 2884.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry # 17
Healthcare Sector # 407
Overall # 2884

Revenue TTM Y/Y Growth Statistics
High Average Low
47.56 %
12.13 %
-8.58 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 17
Sector # 388
S&P 500 # 2724




Other Revenue Growth
Laboratory Analytical Instruments Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ILMN's Revenue Growth Ratio versus Laboratory Analytical Instruments Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Jun 28 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 28 2026
Royalty Pharma Plc16.50%$ 16.499 millions
Acadia Pharmaceuticals Inc 16.40%$ 16.402 millions
Harvard Bioscience Inc 16.35%$ 16.352 millions
Alpha Pro Tech Ltd 15.76%$ 15.765 millions
Armata Pharmaceuticals Inc 15.72%$ 15.722 millions
Lifeward ltd 15.71%$ 15.706 millions
Novocure Limited15.60%$ 15.603 millions
Ufp Technologies Inc 15.56%$ 15.558 millions
Orthopediatrics Corp15.55%$ 15.551 millions
Jazz Pharmaceuticals Plc15.55%$ 15.548 millions
Alphatec Holdings Inc 15.35%$ 15.349 millions
Penumbra Inc14.90%$ 14.904 millions
Rockwell Medical inc 14.69%$ 14.687 millions
Sbc Medical Group Holdings Incorporated14.36%$ 14.363 millions
Nuwellis Inc 14.14%$ 14.145 millions
West Pharmaceutical Services Inc 13.89%$ 13.892 millions
Edwards Lifesciences Corporation13.66%$ 13.657 millions
Indivior Pharmaceuticals Inc 13.58%$ 13.576 millions
Talkspace Inc 13.56%$ 13.556 millions
Atricure Inc 13.38%$ 13.376 millions
Dexcom Inc 13.11%$ 13.105 millions
Sanara Medtech Inc 13.03%$ 13.028 millions
Bausch Health Companies Inc 12.73%$ 12.727 millions
Vertex Pharmaceuticals Inc12.45%$ 12.453 millions
Genedx Holdings Corp 12.30%$ 12.304 millions
Profound Medical Corp 12.30%$ 12.302 millions
Xenetic Biosciences Inc 11.99%$ 11.986 millions
Biolife Solutions Inc 11.98%$ 11.978 millions
Repligen Corp11.93%$ 11.933 millions
Medline Inc 11.60%$ 11.603 millions


About Illumina Inc Revenue Growth Rates (ILMN), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Illumina Inc (CIK 1110803).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001110803-26-000160
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Illumina Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.